Literature DB >> 20662058

How interleukin-1β induces gouty arthritis.

Charles A Dinarello.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20662058      PMCID： PMC3534984          DOI： 10.1002/art.27663

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  14 in total

1.  Successful treatment of chronic tophaceous gout with infliximab (Remicade).

Authors:  Christoph Fiehn; Martin Zeier
Journal:  Rheumatol Int       Date:  2005-06-03       Impact factor: 2.631

2.  MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals.

Authors:  Chun-Jen Chen; Yan Shi; Arron Hearn; Kate Fitzgerald; Douglas Golenbock; George Reed; Shizuo Akira; Kenneth L Rock
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

3.  Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself.

Authors:  R Schindler; J A Gelfand; C A Dinarello
Journal:  Blood       Date:  1990-10-15       Impact factor: 22.113

4.  Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1.

Authors:  P T Chapman; H Yarwood; A A Harrison; C J Stocker; F Jamar; R H Gundel; A M Peters; D O Haskard
Journal:  Arthritis Rheum       Date:  1997-05

5.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

6.  Dissociation between interleukin-1 beta mRNA and protein synthesis in human peripheral blood mononuclear cells.

Authors:  R Schindler; B D Clark; C A Dinarello
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

7.  Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta.

Authors:  Leo A B Joosten; Mihai G Netea; Giamila Fantuzzi; Marije I Koenders; Monique M A Helsen; Helmut Sparrer; Christine T Pham; Jos W M van der Meer; Charles A Dinarello; Wim B van den Berg
Journal:  Arthritis Rheum       Date:  2009-12

8.  Peripheral blood mononuclear cells stimulated with C5a or lipopolysaccharide to synthesize equivalent levels of IL-1 beta mRNA show unequal IL-1 beta protein accumulation but similar polyribosome profiles.

Authors:  R L Kaspar; L Gehrke
Journal:  J Immunol       Date:  1994-07-01       Impact factor: 5.422

9.  A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways.

Authors:  M T Audrey Nguyen; Svetlana Favelyukis; Anh-Khoi Nguyen; Donna Reichart; Peter A Scott; Alan Jenn; Ru Liu-Bryan; Christopher K Glass; Jaap G Neels; Jerrold M Olefsky
Journal:  J Biol Chem       Date:  2007-10-04       Impact factor: 5.157

10.  Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process.

Authors:  E J Giamarellos-Bourboulis; M Mouktaroudi; E Bodar; J van der Ven; B-J Kullberg; M G Netea; J W M van der Meer
Journal:  Ann Rheum Dis       Date:  2008-04-04       Impact factor: 19.103
View more
  19 in total

Review 1.  Targeting inflammation in the treatment of type 2 diabetes: time to start.

Authors:  Marc Y Donath
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

2.  Inflammatory gout: observations over a half-century.

Authors:  Stephen E Malawista; Anne Chevance de Boisfleury; Paul H Naccache
Journal:  FASEB J       Date:  2011-12       Impact factor: 5.191

3.  Innate and adaptive interferons suppress IL-1α and IL-1β production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection.

Authors:  Katrin D Mayer-Barber; Bruno B Andrade; Daniel L Barber; Sara Hieny; Carl G Feng; Patricia Caspar; Sandy Oland; Siamon Gordon; Alan Sher
Journal:  Immunity       Date:  2011-12-23       Impact factor: 31.745

Review 4.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

Authors:  Charles A Dinarello
Journal:  Blood       Date:  2011-02-08       Impact factor: 22.113

Review 5.  Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Rheumatology (Oxford)       Date:  2015-07-23       Impact factor: 7.580

Review 6.  Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis.

Authors:  Bruce N Cronstein; Prashanth Sunkureddi
Journal:  J Clin Rheumatol       Date:  2013-01       Impact factor: 3.517

7.  Contribution of mast cell-derived interleukin-1β to uric acid crystal-induced acute arthritis in mice.

Authors:  Laurent L Reber; Thomas Marichal; Jeremy Sokolove; Philipp Starkl; Nicolas Gaudenzio; Yoichiro Iwakura; Hajime Karasuyama; Lawrence B Schwartz; William H Robinson; Mindy Tsai; Stephen J Galli
Journal:  Arthritis Rheumatol       Date:  2014-10       Impact factor: 10.995

Review 8.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

9.  Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

Authors:  Viola Klück; Tim L Th A Jansen; Matthijs Janssen; Antoaneta Comarniceanu; Monique Efdé; Isak W Tengesdal; Kiki Schraa; Maartje C P Cleophas; Curtis L Scribner; Damaris B Skouras; Carlo Marchetti; Charles A Dinarello; Leo A B Joosten
Journal:  Lancet Rheumatol       Date:  2020-04-08

10.  Effects of Extract from Mangifera indica Leaf on Monosodium Urate Crystal-Induced Gouty Arthritis in Rats.

Authors:  Yan Jiang; Xiao-Ying You; Kong-Long Fu; Wan-Le Yin
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-19       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.